Liver Cancer Connect is a dedicated program of the Hepatitis B Foundation that was created to provide individuals and families with the information and support they need when facing the challenge of primary liver cancer. Although this is a serious diagnosis, there is good reason to have hope because of the many advances made in the early detection, management and treatment of liver cancer.
In the News
The International Liver Cancer Network (ILCN), of which HBF is a member, released a white paper promoting increased effort to improve prevention, early detection and access to care for liver cancer.
After FDA Evaluation, BMS Withdraws Opdivo For Liver Cancer Treatment in Patients Previously Treated with Sorafenib in the U.S.
FDA grants “orphan drug” designation to chemotherapeutic uttroside-B for use in patients with HCC. The drug is in pre-clinical testing.
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma (ASCOPost, May 2020)
Atezolizumab combination improves survival in HCC (Cancer Letter, May 2020)
COVID 2019: What People With Cancer Need to Know (Cancer.net, June 2020)
U.S. FDA approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib
U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys® GALAD score to Help Diagnose HCC
Pan tumor clinical trial is actively recruiting to investigate the effects of nivolumab when given under the skin with or without rHuPH20. Learn more!
FDA has approved cabozantinib (CABOMETYX, Exelixis, Inc.) for patients with hepatocellular carcinoma who have been previously treated with sorafenib
DNA search finds people resistant to liver disease. Can we mimic this effect with a drug? Regeneron and Alnylam Pharmaceutical to partner
Newly discovered anti-cancer protein LHPP prevents uncontrolled proliferation of cancer cells in the liver and may serve as a biomarker for the diagnosis & prognosis of liver cancer